Glucotrack, INC Form 4 insider transactions

Glucotrack, Inc. and Lokahi Therapeutics have completed a strategic business combination, creating a publicly listed platform for healthcare asset identification and advancement.

Glucotrack, Inc. Director Andrew K. Balo increased his beneficial ownership of common stock and stock options, following multiple reverse stock splits by the company.

Glucotrack, Inc. Director Luis Malave reported acquiring additional common stock and stock options, increasing his beneficial ownership.

Glucotrack director Erin Catherine Carter acquired common stock and stock options following a series of reverse stock splits.

Glucotrack, Inc. CEO Paul Goode acquired 42 shares of common stock following the achievement of a third milestone under an Intellectual Property Purchase Agreement.

John A. Ballantyne Revocable Living Trust reports acquisition and disposal of Glucotrack, Inc. stock and warrants following debt conversion and cashless warrant exercise.

Director John Ballantyne reports acquisition of shares and cashless exercise of warrants in GlucoTrack, Inc.

Director Luis Malave reports the acquisition of common stock and exercise of warrants in GlucoTrack, Inc. following a qualified financing and subsequent conversion of a promissory note.

Director Erin Carter reports multiple transactions involving GlucoTrack, Inc. common stock and convertible promissory notes.

CEO Paul Goode reports several transactions involving GlucoTrack, Inc. common stock and derivative securities.

Director Allen Danzig reports the acquisition of common stock in GlucoTrack, Inc. through Form 4 filings.

Director Andrew Balo acquired 4,490 shares of Glucotrack, Inc. common stock on March 26, 2025.

Director Robert Fischell reports acquisitions of Glucotrack, Inc. common stock in a Form 4 filing.

Director Drew Sycoff acquired warrants to purchase 138,000 shares of GlucoTrack common stock in a private placement offering.

GlucoTrack's CEO, Paul Goode, acquired warrants to purchase 42,000 shares of common stock in a private placement offering.

Director and 10% owner Drew Sycoff acquired 182,539.6 shares of GlucoTrack, Inc. at $1.26 per share, increasing his direct holdings.